Thinking About Changing from Semaglutide to Tirzepatide? Here's How to Make That Decision

Why the question of switching comes up, and what it usually means

Most people asking about changing from semaglutide to tirzepatide fall into one of a few camps. They've plateaued on Wegovy and want to know whether a different mechanism might restart progress. They've read about trial results and are wondering whether they're on the right treatment. Or they've heard that tirzepatide (Mounjaro) acts on two receptor pathways rather than one, and they're curious whether that translates to more weight loss for them personally.

All of those are reasonable things to wonder about. The question of semaglutide or tirzepatide doesn't have a universal answer, which is partly why it keeps coming up. What matters is that the question gets answered by someone who can actually see your records, not by a comparison article alone.

One thing worth understanding early: changing treatments isn't the same as restarting from scratch. Depending on your current dose, your tolerance, and how long you've been taking semaglutide, a prescriber will form a view on how to introduce tirzepatide safely. That detail gets decided in a clinical consultation, not by following a general guide. Our prescribers at nume work through exactly this kind of case regularly.

What the trial evidence tells us, and where the head-to-head data sits

Semaglutide 2.4mg (Wegovy) produced around 15% average body-weight reduction over 68 weeks in the STEP 1 trial, published in the New England Journal of Medicine. Tirzepatide, at its highest dose of 15mg, produced around 20–21% average reduction over 72 weeks in SURMOUNT-1, also in the NEJM. Those aren't directly comparable, different trial populations, different durations, different designs.

A direct comparison did eventually happen. In the SURMOUNT-5 trial (72 weeks, 751 adults with obesity and no diabetes), tirzepatide produced greater average weight reduction than semaglutide 2.4mg, a finding that informed NICE's appraisal of tirzepatide (TA1026). The gap narrows with the newer 7.2mg Wegovy dose, approved in the UK in early 2026. None of this means tirzepatide will produce better results for every individual, averages describe populations, not people.

The relevant comparison for someone already taking semaglutide is more specific: what have you achieved so far, at what dose, and over what timeframe? A prescriber uses that information alongside the trial data when forming a clinical view. For a broader look at how the two medicines sit side by side, this comparison of Wegovy and Mounjaro covers the main differences in detail.

Practical factors in a switch (tolerance, timing, and what tirzepatide is

Tirzepatide (Mounjaro) is a dual GIP and GLP-1 receptor agonist) the only medicine of its kind licensed for weight management in the UK. Semaglutide works on the GLP-1 pathway alone. In practice, this means someone who has tolerated semaglutide reasonably well may still experience a fresh period of adjustment when starting tirzepatide, because the body is encountering a second receptor pathway for the first time. If you're unsure how the two medicines relate to each other, this page explaining whether Mounjaro and Wegovy are the same medication sets out the key distinctions clearly.

Tirzepatide starts at 2.5mg, a starter dose designed to give the body time to adjust before the prescriber considers moving upward. Whether someone switching from semaglutide needs to begin at the very lowest step, or can be assessed differently, is a clinical question. There's no rule that applies universally. It depends on which semaglutide dose you've reached, how well you tolerated it, and any other factors your prescriber judges relevant.

On the practicalities: Mounjaro comes as a pre-filled KwikPen, injected once weekly into the abdomen, thigh, or upper arm, rotating sites. If you order through nume, the pen arrives via DPD the next working day, tracked to your door, in a plain box with nothing on the outside to indicate what's inside. Storage is in the fridge between 2–8°C; for the exact room-temperature window if you need to travel, check the Patient Information Leaflet that comes with it, or ask your prescriber. For more on what switching back might look like in the other direction, this page on changing from Mounjaro to Wegovy is worth reading alongside this one.

How to approach the switch, and what a prescriber looks at

The clearest path through this decision is a structured clinical consultation. That means being honest about your current semaglutide dose, your treatment history, what's changed or plateaued, and any other health conditions or medicines you're taking. A prescriber can then form a view on whether switching is appropriate, and if so, how to do it safely. If you've already been researching your options, our dedicated page on changing from semaglutide to tirzepatide walks through the clinical considerations in more depth.

A few things that affect the clinical picture: if you're partway through a semaglutide titration and experiencing side effects, switching might be considered differently than if you've been stable on the maintenance dose for months. If you're taking an oral contraceptive pill, your prescriber should know, tirzepatide can reduce absorption of oral contraceptives, and you may need to use a non-oral method for the first four weeks of treatment and for four weeks after each dose increase, as NHS guidance outlines.

There's also a question of what you're hoping to achieve. If semaglutide has produced meaningful results and the question is purely whether tirzepatide could do more, that's a different conversation from one where results have stalled entirely. Our clinical team (including our lead prescriber) reviews each case individually, with the same rigour whether you're starting treatment for the first time or considering a change. Which treatment suits you is a decision they make with you, not for you. If you're ready to have that conversation, start your free consultation here.